Diabetes, Endocrinology and Nephrology
Revealing new possibilities in diabetes and endocrinology drug development.
Our unique perspective shapes possibilities in diabetes clinical research.
At Covance, our endocrinology professionals leverage their extensive diabetes and lipid disorder experience to help you create streamlined solutions. Whether you are a small biotech or a large-sized pharmaceutical company, we work relentlessly to enable you to achieve specific development milestones.
Finding the cure—faster.
As the prevalence of diabetes continues to grow, the race to find a cure is intensifying. Our therapeutically-focused experts can help you accelerate the process with proven strategies designed to help you reach your development milestones sooner. Let us help you cross the finish line first.
Reach smarter clinical decisions faster with preclinical mechanism-of-action studies
Quantify insulin secretion with customized glucose clamps in healthy normal volunteers and / or patients with Type 1 or Type 2 diabetes
Speed timelines by integrating preclinical safety assessments with proof-of-concept studies
Leverage our experience and operational capabilities in global cardiovascular outcome mega-trials with endpoint adjudication
Start the right trials, pre-IND, and accelerate your market approval by incorporating Market Access and regulatory strategies into early phase designs
In endocrine studies, including diabetes, results depend on comprehensive testing solutions – from the lab to the clinic. We help you achieve success by ensuring fully standardized methodology across all of our five global NGSP Level 1 certified central laboratories, to provide you with exceptionally accurate worldwide data for A1C testing. Couple our testing leadership with our proprietary Xcellerate® knowledgebase that helps you optimize site selection and recruitment, and you’ll have a diabetes program that works harder for you.
Revealing new opportunities to grow your business.
Like you, we are passionate about science. From exploring novel uses for Type 2 diabetes drugs in treating Type 1 disease to proactively addressing potential opportunities for biologics, biosimilars, devices and novel insulin delivery systems, we stay on the cutting edge of diabetes and endocrinology drug development. Our goal is to deliver Solutions Made Real® that set you up for success.
End-to-end solutions to extend your team.
We deliver a holistic suite of diabetes and endocrinology drug development solutions. From lead optimization through commercialization, we are personally invested in maximizing the ROI of your development program.
Connect With a Covance Expert
If you have a question for one of our diabetes/endocrinology experts, please click the button below.
Barry J. Goldstein, MD, PhD, FACE
Vice President & Global Therapeutic Area Head
Dr. Barry Goldstein joined Covance in 2013 as global therapeutic area head for cardiovascular, metabolic, diabetes, endocrinology and renal disease. He is board-certified in endocrinology and diabetes and has over 25 years of experience in clinical and basic research and development in both academia and industry.
His vast experience includes establishing a robust Phase II-IV clinical trials unit in diabetes and endocrinology at Jefferson Medical College where he was principal investigator (PI) or co-PI on nearly 100 clinical trials. Dr. Goldstein is also recognized leader in diabetes research and clinical practice; he is a past associate editor of Diabetes and JCEM and has served on many grant review panels for NIH, ADA and JDRF, as well as industry scientific advisory panels. His contributions to the literature include more than 220 papers, editorials, monographs, textbook chapters and co-editorships.
Barbara S. Gillespie, MD, MMS, FASN
Vice President and Therapeutic Head of Nephrology, Covance
Adjunct Professor, University of North Carolina School of Medicine, Division of Nephrology and Hypertension
Dr. Gillespie joined Covance in 2017 after over a decade of leadership experience at Quintiles, where she held a variety of positions, including working in the Office of the Chief Medical and Scientific Officer, serving as Global Therapeutic Lead for Nephrology and also as North American Head of the US Internal Medicine team. She is currently board certified in nephrology.
Dr. Gillespie serves on the Board of Directors of the Kidney Health Initiative as well as on the Scientific Advisory Board for National Kidney Foundation (NKF) Chronic Kidney Disease (CKD) Registry. She is on the Stakeholder Committee and an Invited Participant for FDA/EMA/NKF Workshop on Renal Endpoints (March 2018). Rounding out her broad nephrology experience, Dr. Gillespie currently works as Associate Medical Director of Nephrology and Dialysis Services at NaphCare in Raleigh, North Carolina.
Darlene C. Deecher, PhD
Executive Director CVMER* Operations, Strategy & Planning
Dr. Darlene Deecher joined Covance in 2013 and brings more than 20 years of applied research and clinical development experience. Dr. Deecher has been a recognized leader in improving drug discovery and development processes to accelerate assets through the pharmaceutical pipeline to meet registration requirements.
Her deep experience includes managing all aspects of drug and device research and operations in glucose control and diabetic complications, including prevention strategies, in her role as senior vice president of research at the Juvenile Diabetes Research Foundation. She also spent 15 years at Wyeth Pharmaceuticals as part of the senior leadership team responsible for discovery, development, life-cycle strategy, commercialization and market launch of various assets within the women’s health, endocrinology and neuroscience therapeutic portfolios, leading the efforts to advance compounds and work closely with registration agencies during the development and launch of new therapies.
Michael D. Cressman, DO
Senior Medical Director, CVMER* Group
Dr. Michael Cressman joined Covance in 2012 and is a board-certified nephrologist with more than 30 years of experience in clinical trials in the cardiovascular, metabolic and renal disease areas. His experience includes various leadership roles at AstraZeneca, including the global medical lead for rosuvastatin’s clinical development and chair of the renal safety knowledge group, which was an interdisciplinary group of experts in renal pathology, physiology, biostatistics or regulatory aspects relevant to the kidney. He also worked as an associate professor of medicine in the Center for Clinical Pharmacology at the University of Pittsburgh Medical Center.
Dr. Cressman has authored numerous publications that are relevant to cardiovascular risk assessment, treatment of hypertension, dyslipidemia, and diabetic kidney disease (DKD) and considerable experience includes with interactions with the FDA and other regulatory agencies on a wide range of renal-related issues.
Jennifer Ennis, MD
Medical Director, Litholink Corporation, A LabCorp Company
Joining Litholink in 2009, Dr. Jennifer Ennis has overseen the medical and clinical aspects of LabCorp’s clinical decision support tools for management of chronic kidney disease, cardiovascular disease and diabetes.
Board-certified in internal medicine and nephrology, Dr. Ennis is also a clinical assistant professor of medicine in the section of nephrology at the University of Illinois at Chicago. In addition to her clinical and teaching responsibilities, she performs clinical research in chronic kidney disease and has authored several abstracts and peer-reviewed publications.
*CVMER – Cardiovascular, Metabolic, Endocrine, Renal